摘要号：158O

标题：A phase 1 first-in-human study of BPB-101, a novel triple functional bispecific antibody targeting GARP/TGF-β complex and PD-L1, in patients with locally advanced or metastatic solid tumors【BPB-101（一种靶向GARP/TGF-β复合物和PD-L1的新型三重功能双特异性抗体）在局部晚期或转移性实体瘤患者中的首次人体I期研究】

讲者：张力 | 中山大学肿瘤防治中心

摘要号：159O

标题：First-in-human study of ES014, a bispecific antibody targeting CD39 and TGF-β as monotherapy in patients with advanced solid tumors.【ES014（一种靶向CD39和TGF-β的双特异性抗体）单药治疗晚期实体瘤患者的首次人体研究】

讲者：李子明 | 上海市胸科医院

摘要号：160MO

标题：BL-M07D1, a novel anti-HER2 antibody-drug conjugate (ADC), in subjects with metastatic HER2-mutant non-small cell lung cancer (NSCLC)【BL-M07D1，一种新型抗 HER2 抗体药物偶联物 （ADC），用于转移性 HER2 突变非小细胞肺癌（NSCLC）患者】

讲者：张力 | 中山大学肿瘤防治中心

摘要号：161MO

标题：Safety and tolerability of a novel PARP7 inhibitor QLS1103 in patients with advanced solid tumors: results from a phase 1 trial【一种新型PARP7抑制剂QLS1103在晚期实体瘤患者中的安全性和耐受性：一期临床试验结果】

讲者：陈华军 | 广东省人民医院

摘要号：162MO

标题：A first-in-human (FIH), dose escalation study of HMPL-A83 (A83), an anti-CD47 monoclonal antibody (mAb) in patients (pts) with advanced solid tumors【抗CD47单克隆抗体HMPL-A83（A83） 在晚期实体瘤患者中的的首次人体剂量递增研究】

讲者：郭晔 | 上海市东方医院

摘要号：163MO

标题：First-in-human phase 1 study of the anti-TIGIT and PVRIG bispecific antibody as monotherapy or with sintilimab for advanced solid tumors【抗TIGIT和PVRIG双特异性抗体作为单药或联合信迪利单抗用于治疗晚期实体瘤的一期首次人体研究 】

讲者：张力 | 中山大学肿瘤防治中心

摘要号：928MO

标题：ARTEMIS-001: A Phase 1 Study of HS-20093 (GSK5764227) in Patients With Non-Small Cell Lung Cancer (NSCLC)【ARTEMIS-001：HS-20093（GSK5764227）在NSCLC患者中的I期研究】

讲者：段建春 | 中国医学科学院肿瘤医院

摘要号：978MO

标题：Sintilimab Plus Platinum-Based Chemotherapy With vs Without Autologous CIK Cell Therapy in Metastatic NSCLC: A Multicenter Randomized Study【信迪利单抗联合铂类基础化疗加或不加自体CIK细胞疗法治疗转移性NSCLC：一项多中心随机研究】

讲者：黄鼎智 | 天津医科大学肿瘤医院

摘要号：929MO

标题：Becotatug (JMT101, Beco) Combined with Docetaxel (Albumin-Bound, HB1801) for the Treatment of Patients (pts) with Locally Advanced Squamous Cell Non-Small Cell Lung Cancer (sqNSCLC) -A randomized control phase II study (BATTLE study)【Becotatug（JMT101, Beco）联合多西他赛（白蛋白结合型，HB1801）治疗局部晚期鳞状细胞非小细胞肺癌（sqNSCLC）患者——一项随机对照II期研究（BATTLE研究）】

讲者：张力 | 中山大学肿瘤防治中心

摘要号：979MO

标题：Plinabulin/Docetaxel vs. Docetaxel in 2L/3L EGFRwt NSCLC after Platinum Regimens (DUBLIN-3): Asian Subgroup Analysis【普那布林/多西他赛对比多西他赛在铂类方案后二/三线（2L/3L）EGFR野生型NSCLC中的应用（DUBLIN-3）：亚洲亚组分析】

讲者：韩宝惠 | 上海市胸科医院

摘要号：975MO

标题：Zongertinib in Asian patients with previously treated advanced HER2-mutant NSCLC【宗艾替尼在既往接受过治疗的晚期HER2突变NSCLC亚洲患者中的应用】

讲者：吴一龙 | 广东省人民医院

摘要号：976MO

标题：Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (NSCLC): results from phase 2 KUNPENG study【伯瑞替尼治疗MET扩增驱动的晚期NSCLC：II期KUNPENG研究结果】

讲者：吴一龙 | 广东省人民医院

摘要号：927MO

标题：Osimertinib (osi) before and after chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFRm NSCLC: Phase 2 NEOLA study interim analysis (IA)【奥希替尼用于不可切除III期EGFR突变NSCLC患者放化疗（CRT）前后的治疗：II期NEOLA研究中期分析】

讲者：陈明 | 中山大学肿瘤防治中心

摘要号：87MO

标题：Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer: The CAPItello-290 Phase III trial extended China cohort 【卡匹色替+紫杉醇作为转移性三阴性乳腺癌一线治疗：III期CAPItello-290试验扩展中国队列】

讲者：王树森 | 中山大学肿瘤防治中心

摘要号：88MO

标题：Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of Asian patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): a DESTINY-Breast09 analysis【德曲妥珠单抗（T-DXd）+帕妥珠单抗（P）对比紫杉类+曲妥珠单抗+帕妥珠单抗（THP）用于亚洲HER2阳性晚期/转移性乳腺癌患者一线治疗：DESTINY-Breast09分析】 

讲者：江泽飞 | 中国人民解放军总医院

摘要号：89MO

标题：Phase I/Ib data of SMP-656: a novel Eribulin-based HER2 ADC in solid tumor 【SMP-656（一种新型基于艾日布林的HER2 ADC）在实体瘤中的I/Ib期数据】

讲者：张剑 | 复旦大学附属肿瘤医院

摘要号：90MO

标题：Preliminary efficacy and safety of FDA022-BB05 in advanced/metastatic HER2 low breast cancer: Results from a phase 2 study【FDA022-BB05在晚期/转移性HER2低表达乳腺癌中的初步疗效和安全性：一项II期研究结果 】

讲者：刘晓军 | 复旦大学附属肿瘤医院

摘要号：65MO

标题：Neoadjuvant HLX11 versus European union       (EU)-sourced pertuzumab in human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-negative early or locally advanced, breast cancer (BC): A double-blind, randomised phase 3 equivalence study【新辅助HLX11对比欧盟（EU）来源帕妥珠单抗治疗HER2阳性、HR阴性早期或局部晚期乳腺癌：一项双盲、随机III期等效性研究】

讲者：刘强 | 中山大学孙逸仙纪念医院

摘要号：1MO

标题：Association of genetic risk, DEHP exposure, and their interaction with breast cancer and breast cancer-related mortality【遗传风险、DEHP暴露及其相互作用与乳腺癌及乳腺癌相关死亡率的关联】

讲者：Lijuan Tang | 成都

摘要号：3MO

标题：Axillary Management Strategies in Breast Cancer Patients With ypN0 After Neoadjuvant Therapy【新辅助治疗后达到ypN0乳腺癌患者的腋窝处理策略】

讲者：Qingyao Shang | 北京中国医学科学院北京协和医学院

摘要号：601O

标题：From Slides to Signals: A Multimodal Deep Learning Framework Decoding Platinum Resistance in Ovarian Cancer 【从切片到信号：解码卵巢癌铂类耐药的多模态深度学习框架】

讲者：Enyu Tang | 北京

摘要号：602O

标题：Efficacy and Safety of HLX43 (an anti-PD-L1 ADC) in Recurrent/Metastatic Cervical Cancer (CC): a Randomised, Multicentre, Phase 2 Study【HLX43（一种抗PD-L1 ADC）在复发/转移性宫颈癌（CC）中的疗效和安全性：一项随机、多中心、II期研究】

讲者：于金明 | 山东第一医科大学附属肿瘤医院

摘要号：603O

标题：DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced cervical cancer or platinum-resistant recurrent ovarian cancer【DB-1311/BNT324（一种新型B7H3抗体偶联药物）在晚期宫颈癌或铂类耐药复发性卵巢癌患者中的应用】

讲者：Chih-Long Chang | 中国台湾

摘要号：606MO

标题：Efficacy of Neoadjuvant Anti-PD-1 Immunotherapy Plus Chemotherapy in Locally Advanced Cervical Cancer【新辅助抗PD-1免疫疗法联合化疗在局部晚期宫颈癌中的疗效】

讲者：Liang Wen | 北京

摘要号：607MO

标题：Iparomlimab and tuvonralimab (QL1706) vs zimberelimab for previously treated recurrent/metastatic cervical cancer (r/mCC): An unanchored matching-adjusted indirect comparison (MAIC)【Iparomlimab和tuvonralimab（QL1706）对比zimberelimab用于既往治疗过的复发/转移性宫颈癌（r/mCC）：非锚定匹配调整间接比较 （MAIC）】

讲者：吕晓娟 | 浙江省肿瘤医院

摘要号：608MO

标题：Reduction of cell viability by immune-checkpoint inhibitor in co-cultured organoids derived from high-risk endometrial cancer patients pretreated with PARP inhibitor【免疫检查点抑制剂降低源自接受PARP抑制剂预处理的高危子宫内膜癌患者的共培养类器官的细胞活力】

讲者：Wai Sun Chan | 中国香港

摘要号：609MO

标题：Tisotumab vedotin vs investigator’s choice of chemotherapy as second- or third-line (2L/3L) treatment for Chinese patients (pts) with recurrent or metastatic cervical cancer (r/mCC) in innovaTV 301【在 innovaTV 301 研究中，Tisotumab vedotin 与研究者选择的化疗作为中国复发或转移性宫颈癌 （r/mCC） 患者二线或三线 （2L/3L） 治疗】

讲者：安菊生 | 中国医学科学院肿瘤医院

摘要号：610MO

标题：Optimal adjuvant radiotherapy strategy for cervical cancer: a multi-center database cohort study【宫颈癌的最佳辅助放疗策略：多中心数据库队列研究】

讲者：Fang BAI | 上海

摘要号：666O

标题：Exploration of the efficacy of nimotuzumab combined with induction chemotherapy in locally advanced nasopharyngeal carcinoma: A multicenter, prospective phase 3 study【尼妥珠单抗联合诱导化疗在局部晚期鼻咽癌中的疗效探索：一项多中心、前瞻性III期研究】

讲者：王孝深 | 复旦大学附属眼耳鼻喉科医院

摘要号：669MO

标题：Long Term Overall Survival Follow-up of Toripalimab versus Placebo in Combination with Gemcitabine and Cisplatin as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma 【特瑞普利单抗对比安慰剂联合吉西他滨和顺铂作为复发或转移性鼻咽癌一线治疗的长期总生存随访】

讲者：麦海强 | 中山大学肿瘤防治中心

摘要号：670MO

标题：Efficacy and Safety of Liposomal Irinotecan plus Nimotuzumab in Immune Checkpoint Inhibitor–Refractory Recurrent or Metastatic Nasopharyngeal Carcinoma: A Single-arm, Open-label, Phase 2 trial【脂质体伊立替康联合尼妥珠单抗在免疫检查点抑制剂耐药的复发或转移性鼻咽癌中的疗效和安全性：一项单臂、开放标签、II期试验】

讲者：Shuiqing He | 广州

摘要号：671MO

标题：Long-Term Outcomes of Reduced-Dose Radiotherapy in Patients with Epstein-Barr Virus DNA-Selected Stage III Nasopharyngeal Carcinoma: A 5-Year Follow-Up Secondary Analysis of a Phase II Trial【Epstein-Barr病毒DNA选择的III期鼻咽癌患者减剂量放疗的长期结局：一项II期试验的5年随访二次分析】

讲者：郭姗姗 | 中山大学肿瘤防治中心

摘要号：672MO

标题：Efficacy of Immunotherapy Rechallenge in Locoregionally Advanced Nasopharyngeal Carcinoma After Progression on Prior Immunotherapy: A Real-Word Analysis【既往免疫治疗进展后局部晚期鼻咽癌患者再次挑战免疫治疗的疗效：一项真实世界分析】

讲者：Jiarui He | 广州

摘要号：673MO

标题：Optimizing Induction Chemotherapy Cycles in Locally Advanced Nasopharyngeal Carcinoma: A Recursive Partitioning Risk Stratification Analysis【优化局部晚期鼻咽癌诱导化疗周期数：一项基于递归分区的风险分层分析】

讲者：Jie Yi Lin | 广州

摘要号：674MO

标题：Neoadjuvant application of Pembrolizumab and Chemotherapy in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC): A Single-Arm, Single-Center Phase 2 Study【帕博利珠单抗和化疗在可切除局部晚期头颈部鳞状细胞癌（LA HNSCC）中的新辅助应用：一项单臂、单中心II期研究】

讲者：Kai Wang | 北京

摘要号：675MO

标题：A prospective, multi-center phase II study: Evaluating the efficacy and safety of pembrolizumab combined with chemotherapy as neoadjuvant therapy in laryngeal/hypopharyngeal squamous cell carcinoma (L/HPSCC)【一项前瞻性、多中心II期研究：评估帕博利珠单抗联合化疗作为喉/下咽鳞状细胞癌（L/HPSCC）新辅助治疗的疗效和安全性】

讲者：陈晓红 | 首都医科大学附属北京同仁医院

摘要号：676MO

标题：Neoadjuvant chemo-immunotherapy with camrelizumab plus chemotherapy in resectable or potentially resectable locally advanced head and neck squamous cell carcinoma: an open-label, single-arm, phase II trial【卡瑞利珠单抗联合化疗用于可切除或潜在可切除局部晚期头颈部鳞状细胞癌的新辅助化免治疗：一项开放标签、单臂、II期试验】

讲者：苗素生 | 哈尔滨医科大学附属肿瘤医院

摘要号：271O

标题：Final Analysis and Biomarker Evaluation of JUPITER-06: A Phase 3 Trial of Toripalimab Plus Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma【JUPITER-06最终分析及生物标志物评估：特瑞普利单抗联合化疗治疗晚期或转移性食管鳞状细胞癌的III期试验】

讲者：王峰 | 中山大学肿瘤防治中心

摘要号：198MO

标题：MK-1084 for KRAS G12C-mutated advanced colorectal cancer (CRC): Updated findings from KANDLELIT-001【MK-1084治疗KRAS G12C突变晚期结直肠癌（CRC）：KANDLELIT-001研究最新结果】

讲者：薛俊丽 | 上海市东方医院

摘要号：274MO

标题：Pooled efficacy and safety with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from  China extension cohort, and Hong Kong (HK) and Taiwan (TW) subgroups from the global cohort in the Phase 3 HIMALAYA study【在III期HIMALAYA研究中，中国大陆扩展队列以及全球队列中中国香港（HK）和中国台湾（TW）亚组的不可切除肝细胞癌（uHCC）患者使用tremelimumab联合度伐利尤单抗的汇总疗效和安全性】

讲者：George K. K. Lau | 中国香港

摘要号：275MO

标题：Overall efficacy outcomes of nivolumab plus ipilimumab by occurrence of immune-mediated adverse events (IMAEs) and additional safety from Asian patients in CheckMate 9DW 【纳武利尤单抗联合伊匹木单抗的总体疗效结局与免疫介导不良事件（IMAEs）发生率的关系及亚洲患者额外安全性数据（来自CheckMate 9DW研究）】

讲者：Thomas Yau | 中国香港

摘要号：277MO

标题：Efficacy and safety of adebrelimab combined with S-1 plus oxaliplatin in neoadjuvant therapy for locally advanced gastric adenocarcinoma【阿得贝利单抗联合S-1加奥沙利铂用于局部晚期胃腺癌新辅助治疗的疗效和安全性】

讲者：杨建军 | 空军军医大学西京医院

摘要号：487O

标题：Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): Phase 3 CAPItello-281 Chinese subgroup analysis【卡匹色替+阿比特龙对比安慰剂+阿比特龙治疗PTEN缺陷的初诊转移性激素敏感性前列腺癌（mHSPC）患者：III期CAPItello-281研究中国亚组分析】

讲者：曾浩 | 四川大学华西医院

摘要号：488O

标题：MRI-targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: a multicenter, paired, noninferiority, observational trial【前列腺癌中基于MRI靶向活检联合指数病灶同侧或双侧系统性活检：一项多中心、配对、非劣效性、观察性试验】

讲者：Yongbing Cheng | 南京

摘要号：540O

标题：Fruquintinib monotherapy as second-line (2L) treatment in locally advanced or metastatic renal cell carcinoma (RCC): results from phase 2 part of FRUSICA-2【呋喹替尼单药作为局部晚期或转移性肾细胞癌（RCC）二线治疗：FRUSICA-2研究II期部分结果】

讲者：叶定伟 | 复旦大学附属肿瘤医院

摘要号：489MO

标题：A multicenter, single-arm, phase 2 trial of androgen deprivation therapy in combination with apalutamide in patients with high risk of recurrence after radical prostatectomy (ARES study)【多中心单臂II期试验：雄激素剥夺疗法联合阿帕他胺用于根治性前列腺切除术后高复发风险患者（ARES研究）】

讲者：Qing Zhang | 南京

摘要号：490MO

标题：Niraparib (NIRA) and Abiraterone Acetate plus Prednisone (AAP) in Chinese Patients with breast cancer susceptibility gene (BRCA) altered metastatic castration-sensitive prostate cancer (mCSPC): Subgroup Analysis of the Phase 3 AMPLITUDE Trial【尼拉帕利（NIRA）联合醋酸阿比特龙+泼尼松（AAP）治疗中国乳腺癌易感基因（BRCA）突变的转移性去势敏感性前列腺癌（mCSPC）患者：III期AMPLITUDE试验亚组分析 】

讲者：叶定伟 | 复旦大学附属肿瘤医院

摘要号：541MO

标题：Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy for muscle-invasive bladder cancer: A multi-center, single-arm, phase II trial【维迪西妥单抗联合吉西他滨作为肌层浸润性膀胱癌新辅助治疗的疗效与安全性：多中心单臂II期试验 】

讲者：Chu Yang | 武汉

摘要号：542MO

标题：Efficacy and safety of disitamab vedotin (DV) combined with tislelizumab as adjuvant therapy after radical surgery for patients with HER2-expression upper tract urothelial carcinoma (UTUC): A single-arm, prospective, phase Ⅱ study【维迪西妥单抗联合替雷利珠单抗作为HER2表达上尿路尿路上皮癌（UTUC）根治术后辅助治疗的疗效与安全性：单臂前瞻性II期研究 】

讲者：顾良友 | 中国人民解放军总医院

摘要号：547MO

标题：Efficacy and Safety of Toripalimab Combined with Lenvatinib as First-Line Treatment for Unresectable/Advanced Non–Clear Cell Renal Cell Carcinoma: A Prospective, Single-arm, Phase II trial【特瑞普利单抗联合仑伐替尼一线治疗不可切除/晚期非透明细胞肾细胞癌的疗效与安全性：前瞻性单臂II期试验 】

讲者：顾良友 | 中国人民解放军总医院

摘要号：740MO

标题：Enhancing Community Palliative Care in Advanced Cancer Using SUPPORT+: A Randomized Trial Subgroup Analysis in Older Adults【使用SUPPORT+加强晚期癌症患者的社区姑息治疗：一项针对老年人的随机试验亚组分析】

讲者：Wendy W. Chan | 中国香港